Stock PMCB PHARMACYTE BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News PharmaCyte Biotech, Inc.

Equities

PMCB

US71715X2036

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.11 USD -0.47% Intraday chart for PharmaCyte Biotech, Inc. -0.47% -2.31%
Mar. 18 PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
2023 PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
CI
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors
CI
Femasys Inc. announces tranche update
CI
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
AQ
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
BU
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.
CI
PharmaCyte Biotech : Change in Certifying Accountants - Form 8-K
PU
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
BU
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
BU
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology
CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023
CI
PharmaCyte Biotech : Certificate of Incorporation/Bylaws - Form 8-K
PU
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023
CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on May 11, 2023.
CI
PharmaCyte Biotech Announces Final Results of Tender Offer
BU
PharmaCyte Biotech, Inc.'s Equity Buyback announced on May 11, 2023, has closed with 8,085,879 shares, representing 48.15% for $26.46 million.
CI
PHARMACYTE BIOTECH, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PMCB Stock
  4. News PharmaCyte Biotech, Inc.